Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Metabolic Panel Testing Market size was valued at USD 12.23 billion in 2024 and is expected to reach USD 37.05 billion by 2037, expanding at around 8.9% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of metabolic panel testing is assessed at USD 13.16 billion.
The growth of the market can be attributed to the increasing awareness among people regarding early diagnosis and treatment of diseases, and growing prevalence of chronic diseases around the world. Along with these, rising number of incidences lifestyle-associated diseases, including obesity, coupled with the escalating adoption of unhealthy habits such as smoking, excessive drinking and lack of physical activities are also expected to drive significant market growth in the forthcoming years. According to the World Health Organization (WHO), about 38.2 million children under the age of 5 years were overweight or obese in the year 2019. Worldwide obesity has grown by more than 3 times since 1975. Furthermore, developments in point-of-care technologies and diagnostics globally are projected to offer lucrative opportunities for market growth in the near future.
Metabolic Panel Testing Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Awareness Among People Regarding Early Diagnosis and Treatment of Diseases
- Growing Prevalence of Chronic Diseases Around the World
Challenges
- High Cost of Metabolic Panel Testing
Metabolic Panel Testing Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.9% |
|
Base Year Market Size (2024) |
USD 12.23 billion |
|
Forecast Year Market Size (2037) |
USD 37.05 billion |
|
Regional Scope |
|
Metabolic Panel Testing Segmentation
The market is segmented by disease into kidney diseases, diabetes, liver diseases, and others, out of which, the kidney diseases segment is anticipated to hold the largest share in the global metabolic panel testing market. This can be accounted to the growing occurrence of kidney diseases, and rapid shift in the lifestyle of people worldwide. Apart from this, the diabetes segment is predicted to observe significant growth over the forecast period owing to the increasing cases of diabetes and cardiovascular diseases, and rising demand for immediate diagnosis of these diseases. Additionally, on the basis of end user, the laboratories segment is assessed to grab the largest share over the forecast period ascribing to the high preference of patients to get test results from reputed laboratories, and their affiliation with blood banks, hospitals and specialty diagnostic centers.
Our in-depth analysis of the global market includes the following segments
|
By Disease |
|
|
By Test Type |
|
|
By End-User
|
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportMetabolic Panel Testing Industry - Regional Synopsis
Regionally, the global metabolic panel testing market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Asia Pacific industry is expected to dominate majority revenue share by 2037, impelled by improvements in healthcare infrastructure, and rising disposable income in the region.
North America Market Analysis
Moreover, the market in North America is expected to grab the largest share during the forecast period owing to the high healthcare spending, and strong commercial presence of metabolic panel diagnostics in the region. As per the Centers for Medicare & Medicaid Services (CMS), the healthcare spending in the United States grew by 9.7 percent in 2020, amounting for a value of USD 1.4 trillion. As a share of the nation's GDP, health spending accounted for 19.7 percent. In addition, favorable reimbursement policies provided by the government is also projected to drive market growth in the region in the coming years.
Companies Dominating the Metabolic Panel Testing Landscape
- SYNLAB International GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Abbott Laboratories
- Quest Diagnostics, Inc.
- Laboratory Corporation of America Holdings
- Sonic Healthcare Limited
- Associated Regional and University Pathologists, Inc.
- Nova Biomedical
- WerfenLife, S.A.
- Scion Lab Services, LLC
In the News
-
April 2020- Nova Biomedical declared that the U.S. Food and Drug Administration (FDA) approved its Stat Profile Prime Plus critical care blood gas analyzer for point-of-care use. The technology provides 19 essential critical care tests, including blood gases, electrolytes, metabolites, hematology, and co-oximetry.
-
June 2021- Abbott launched rapid point-of-care HBA1C test to help professionals in the diagnosis of diabetes and the assessment of patient’s risk to develop the condition.
Author Credits: Radhika Pawar
- Report ID: 3994
- Published Date: Dec 26, 2024
- Report Format: PDF, PPT
